Development and Biological Characterization of a Novel Selective TrkA Agonist with Neuroprotective Properties against Amyloid Toxicity
Authors:
- Thanasis RogdakisTRThanasis Rogdakis
- Despoina CharouDCDespoina Charou
- Alessia LatorrataAlessia Latorrata
- Eleni PapadimitriouEPEleni Papadimitriou
- Alexandros TsengenesATAlexandros Tsengenes
- Christina AthanasiouCAChristina Athanasiou
- Marianna PapadopoulouMPMarianna Papadopoulou
- Constantina ChalikiopoulouCCConstantina Chalikiopoulou
- Theodora KatsilaTheodora Katsila
- Isbaal RamosIRIsbaal Ramos
- Kyriakos C. ProusisKPKyriakos C. Prousis
- Rebecca C. WadeRebecca C. Wade
Open Access
- 6 March 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (3) , 614
Abstract
Neurotrophins are growth factors that exert important neuroprotective effects by preventing neuronal death and synaptic loss. Nerve Growth Factor (NGF) acts through the activation of its high-affinity, pro-survival TrkA and low-affinity, pro-apoptotic p75NTR receptors. NGF has been shown to slow or prevent neurodegenerative signals in Alzheimer’s Disease (AD) progression. However, its low bioavailability and its blood–brain-barrier impermeability limit the use of NGF as a potential therapeutic agent against AD. Based on our previous findings on synthetic dehydroepiandrosterone derivatives, we identified a novel NGF mimetic, named ENT-A013, which selectively activates TrkA and exerts neuroprotective, anti-amyloid-β actions. We now report the chemical synthesis, in silico modelling, metabolic stability, CYP-mediated reaction phenotyping and biological characterization of ENT-A013 under physiological and neurodegenerative conditions. We show that ENT-A013 selectively activates the TrkA receptor and its downstream kinases Akt and Erk1/2 in PC12 cells, protecting these cells from serum deprivation-induced cell death. Moreover, ENT-A013 promotes survival of primary Dorsal Root Ganglion (DRG) neurons upon NGF withdrawal and protects hippocampal neurons against Amyloid β-induced apoptosis and synaptic loss. Furthermore, this neurotrophin mimetic partially restores LTP impairment. In conclusion, ENT-A013 represents a promising new lead molecule for developing therapeutics against neurodegenerative disorders, such as Alzheimer’s Disease, selectively targeting TrkA-mediated pro-survival signals.Keywords
Funding Information
- European Union’s Horizon 2020 research and innovation programme “Euroneurotrophin” under the Marie Skłodowska-Curie grant agreement No 765704. (765704)
This publication has 83 references indexed in Scilit:
- Low molecular weight, non-peptidic agonists of TrkA receptor with NGF-mimetic activityCell Death & Disease, 2012
- Neurosteroid Dehydroepiandrosterone Interacts with Nerve Growth Factor (NGF) Receptors, Preventing Neuronal ApoptosisPLOS Biology, 2011
- Regulation of matrix metalloproteinase 2 by oligomeric amyloid β proteinBrain Research, 2011
- PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKaPredictionsJournal of Chemical Theory and Computation, 2011
- Amitriptyline is a TrkA and TrkB Receptor Agonist that Promotes TrkA/TrkB Heterodimerization and Has Potent Neurotrophic ActivityChemistry & Biology, 2009
- Highly Enantio- and Diastereoselective One-Pot Methods for the Synthesis of Halocyclopropyl AlcoholsJournal of the American Chemical Society, 2008
- Neurotrophin-regulated signalling pathwaysPhilosophical Transactions of the Royal Society B: Biological Sciences, 2006
- Dehydroepiandrosterone (DHEA) increases production and release of Alzheimer's amyloid precursor proteinLife Sciences, 1996
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996
- Comparative Protein Modelling by Satisfaction of Spatial RestraintsJournal of Molecular Biology, 1993